Fevertree Drinks remains an attractive premium mixer brand, trading at a reasonable valuation after past volatility and a strong net cash position. Margin expansion, robust free cash flow, and aggressive share buybacks support FQVTF's investment case, despite temporary headwinds from the Molson Coors partnership. The Molson Coors deal enhances U.S. distribution and onshores production, promising long-term cost savings and revenue growth for FQVTF.
Fevertree Drinks Plc said it is trading in line with expectations, in a statement ahead of today's annual general meeting. The tonic and mixer maker forecasts low single-digit revenue growth and an adjusted EBITDA margin of around 12% for its financial year.
Fevertree Drinks PLC has issued £71 million worth of shares to Molson Coors after the duo penned an agreement for its carbonated mixer brand in the US. Some 10,856,628 ordinary shares were issued at a price of 654.2p each, Fevertree said Wednesday, equating to 8.5% of the company.
Coors Light beer maker Molson Coors will take a 8.5% stake in UK's Fevertree Drinks for 71 million pounds ($88.3 million) to expand its portfolio of non-alcoholic beverage offerings in the U.S., the companies said on Thursday.
Fever-Tree Drinks PLC (OTCPK:FQVTF) Q2 2024 Earnings Conference Call September 12, 2024 5:00 AM ET Company Participants Tim Warrillow - CEO Andy Branchflower - CFO Charles Gibb - CEO, North America Conference Call Participants Edward Mundy - Jefferies Rashad Kawan - Morgan Stanley Anubhav Malhotra - Panmure Liberum Matthew Ford - BNP Paribas Tim Warrillow Good morning, everyone, and thank you for joining us to hear about Fever-tree's performance in the First Half of 2024. My name is Tim Warrillow, Co-Founder and CEO of Fever-tree and I'm joined on the call by Andy Branchflower, CFO; and Charles Gibb, who has very nobly got up very early in the morning, our North American CEO.
Fevertree Drinks' stock price already has some upside going by the forward price-to-earnings (P/E) ratio, and its dividends as well as improving market conditions indicate further upside is likely. The company has a reasonable 8% revenue growth projection for 2024, but it expects adjusted EBITDA to double as inflationary pressures calm down. I wouldn't rule out upgrades to projections going by the momentum indicated in its latest trading update, as well as better health in its big UK market.